title: Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis.
abstract: Psoriasis is a common skin condition affecting approximately 2.6% of the population in the US. The most effective current therapies for psoriasis have suppressive activity against T lymphocytes directly or by modulating the biologic effects of inflammatory cytokines. Tacrolimus has been used successfully to treat a number of T cell-mediated diseases. UVA1 has been shown to induce T lymphocyte apoptosis. Combination treatment is commonly used in the management of psoriasis. Therefore, this pilot study was performed to evaluate if the combination of medium-dose UVA1 (50 J/cm2) and tacrolimus ointment is effective for the treatment of palmar plantar psoriasis. A total of 5 patients completed the study of 30 UVA1 treatments, and another patient completed half of the treatments. No dramatic changes in plaque thickness or scaling were seen with either tacrolimus alone or with the combination of tacrolimus and medium dose UVA1 on palmar or plantar psoriasis.
authors.affiliation: Department of Dermatology, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Rivard
authors.forename: Jennifer
authors.initials: J
authors.lastname: Janiga
authors.forename: Henry W
authors.initials: HW
authors.lastname: Lim
mesh_terms: D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009824:Ointments; D011565:Psoriasis / Q000145:classification / Q000188:drug therapy*; D012720:Severity of Illness Index; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods*
chemical_list: D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus